Mangoceuticals, Total Other Income Expense Net from 2010 to 2024

MGRX Stock   2.50  0.03  1.19%   
Mangoceuticals, Common Total Other Income Expense Net yearly trend continues to be fairly stable with very little volatility. Total Other Income Expense Net is likely to outpace its year average in 2024. During the period from 2010 to 2024, Mangoceuticals, Common Total Other Income Expense Net regression line of annual values had significance of  0 and arithmetic mean of (42,174). View All Fundamentals
 
Total Other Income Expense Net  
First Reported
2010-12-31
Previous Quarter
6.5 K
Current Value
6.8 K
Quarterly Volatility
23.2 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Mangoceuticals, Common financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mangoceuticals, Common's main balance sheet or income statement drivers, such as Depreciation And Amortization of 26.4 K, Interest Expense of 0.0 or Selling General Administrative of 6.8 M, as well as many indicators such as Price To Sales Ratio of 7.7, Dividend Yield of 0.0 or PTB Ratio of 8.03. Mangoceuticals, financial statements analysis is a perfect complement when working with Mangoceuticals, Common Valuation or Volatility modules.
  
Check out the analysis of Mangoceuticals, Common Correlation against competitors.

Latest Mangoceuticals, Common's Total Other Income Expense Net Growth Pattern

Below is the plot of the Total Other Income Expense Net of Mangoceuticals, Common Stock over the last few years. It is Mangoceuticals, Common's Total Other Income Expense Net historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Mangoceuticals, Common's overall financial position and show how it may be relating to other accounts over time.
Total Other Income Expense Net10 Years Trend
Slightly volatile
   Total Other Income Expense Net   
       Timeline  

Mangoceuticals, Total Other Income Expense Net Regression Statistics

Arithmetic Mean(42,174)
Coefficient Of Variation(54.96)
Mean Deviation17,776
Median(53,284)
Standard Deviation23,177
Sample Variance537.2M
Range60.1K
R-Value0.70
Mean Square Error296.5M
R-Squared0.49
Significance0
Slope3,618
Total Sum of Squares7.5B

Mangoceuticals, Total Other Income Expense Net History

2024 6796.65
2023 6473.0
2022 -6473.0

About Mangoceuticals, Common Financial Statements

Mangoceuticals, Common investors use historical fundamental indicators, such as Mangoceuticals, Common's Total Other Income Expense Net, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Mangoceuticals, Common. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Other Income Expense Net6.5 K6.8 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Mangoceuticals, Stock Analysis

When running Mangoceuticals, Common's price analysis, check to measure Mangoceuticals, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangoceuticals, Common is operating at the current time. Most of Mangoceuticals, Common's value examination focuses on studying past and present price action to predict the probability of Mangoceuticals, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangoceuticals, Common's price. Additionally, you may evaluate how the addition of Mangoceuticals, Common to your portfolios can decrease your overall portfolio volatility.